CoLucid Pharmaceuticals, a biotech developing treatments for migraine headaches, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The Burlington, MA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol CLCD. CoLucid Pharmaceuticals initially filed confidentially on February 24, 2015. Piper Jaffray and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
